Skip to main content
Journal cover image

The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.

Publication ,  Journal Article
Zhang, T; Hwang, JK; George, DJ; Pal, SK
Published in: Cancer Treat Res Commun
2020

Since the approval of immunotherapy checkpoint inhibitors for first-line treatment of metastatic renal cell carcinoma, new and clinically relevant questions have emerged that ongoing clinical trials and trials in development will address. These questions include how to integrate combination immunotherapy approaches like ipilimumab/nivolumab with targeted therapies against vascular endothelial growth factor (VEGF) receptors, which patients can discontinue treatment, and who needs ipilimumab to maximize clinical responses. Furthermore, with new approvals of treatment regimens combining checkpoint inhibitors with targeted therapies, new questions arise in the clinic regarding optimal treatment selection for first-line clear cell renal cell carcinoma. This review will highlight the contemporary clinical trials in metastatic clear cell renal cell carcinoma that try to address some of these knowledge gaps.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Treat Res Commun

DOI

EISSN

2468-2942

Publication Date

2020

Volume

24

Start / End Page

100183

Location

England

Related Subject Headings

  • Time-to-Treatment
  • Time Factors
  • Receptors, Vascular Endothelial Growth Factor
  • Randomized Controlled Trials as Topic
  • Protein Kinase Inhibitors
  • Progression-Free Survival
  • Nephrectomy
  • Neoadjuvant Therapy
  • Kidney Neoplasms
  • Kidney
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhang, T., Hwang, J. K., George, D. J., & Pal, S. K. (2020). The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma. Cancer Treat Res Commun, 24, 100183. https://doi.org/10.1016/j.ctarc.2020.100183
Zhang, Tian, Joyce K. Hwang, Daniel J. George, and Sumanta K. Pal. “The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.Cancer Treat Res Commun 24 (2020): 100183. https://doi.org/10.1016/j.ctarc.2020.100183.
Zhang T, Hwang JK, George DJ, Pal SK. The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma. Cancer Treat Res Commun. 2020;24:100183.
Zhang, Tian, et al. “The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.Cancer Treat Res Commun, vol. 24, 2020, p. 100183. Pubmed, doi:10.1016/j.ctarc.2020.100183.
Zhang T, Hwang JK, George DJ, Pal SK. The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma. Cancer Treat Res Commun. 2020;24:100183.
Journal cover image

Published In

Cancer Treat Res Commun

DOI

EISSN

2468-2942

Publication Date

2020

Volume

24

Start / End Page

100183

Location

England

Related Subject Headings

  • Time-to-Treatment
  • Time Factors
  • Receptors, Vascular Endothelial Growth Factor
  • Randomized Controlled Trials as Topic
  • Protein Kinase Inhibitors
  • Progression-Free Survival
  • Nephrectomy
  • Neoadjuvant Therapy
  • Kidney Neoplasms
  • Kidney